{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:55:08Z","timestamp":1720400108470},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T00:00:00Z","timestamp":1496361600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s40268-017-0189-5","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T05:28:55Z","timestamp":1496381335000},"page":"397-402","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis"],"prefix":"10.1007","volume":"17","author":[{"given":"Koichiro","family":"Homma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Shiina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneki","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Homma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,2]]},"reference":[{"issue":"Suppl 2","key":"189_CR1","doi-asserted-by":"crossref","first-page":"s276","DOI":"10.2337\/dc11-s229","volume":"34","author":"D Dicker","year":"2011","unstructured":"Dicker D. DPP-4 inhibitors. Impact on glycemic control and cardiovascular risk factors. Diabetic Care. 2011;34(Suppl 2):s276\u20138.","journal-title":"Diabetic Care"},{"key":"189_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1463-1326.2010.01306.x","volume":"13","author":"CF Deacon","year":"2011","unstructured":"Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13:7\u201318.","journal-title":"Diabetes Obes Metab."},{"key":"189_CR3","first-page":"287","volume":"6","author":"E Kutoh","year":"2014","unstructured":"Kutoh E, Hirate M, Ikeno Y. Teneligliptin as an initial therapy for newly diagnosed, drug na\u00efve subjects with type 2 diabetes. J Clin Med Res. 2014;6:287\u201394.","journal-title":"J Clin Med Res."},{"key":"189_CR4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0022-2275(20)38659-4","volume":"28","author":"BV Howard","year":"1987","unstructured":"Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res. 1987;28:613\u201328.","journal-title":"J Lipid Res."},{"key":"189_CR5","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/diacare.27.6.1496","volume":"27","author":"RM Krauss","year":"2004","unstructured":"Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabet Care. 2004;27:1496\u2013504.","journal-title":"Diabet Care"},{"key":"189_CR6","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.2337\/db08-0787","volume":"57","author":"K Williams","year":"2008","unstructured":"Williams K, Tchermof A, Hunt KJ, Wagenknecht LE, Haffner SM, Sniderman AD. Diabetes, abdominal adiposity, and atherogenic dyslipoproteinemia in women compared with men. Diabetes. 2008;57:3289\u201396.","journal-title":"Diabetes."},{"key":"189_CR7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/ki.1991.22","volume":"39","author":"G Appel","year":"1991","unstructured":"Appel G. Lipid abnormalities in renal disease. Kidney Int. 1991;39:169\u201383.","journal-title":"Kidney Int"},{"key":"189_CR8","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1681\/ASN.2006091006","volume":"18","author":"BCK Kwan","year":"2007","unstructured":"Kwan BCK, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007;18:1246\u201361.","journal-title":"J Am Soc Nephrol."},{"key":"189_CR9","first-page":"2705","volume-title":"The metabolic and molecular bases of inherited disease","author":"RJ Havel","year":"2001","unstructured":"Havel RJ, Kane JP. Introduction: structure and metabolism of plasma lipoproteins. In: Scriver SPR, Beaudet AL, Sly WS, Valle DV, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 2705\u201316.","edition":"8"},{"key":"189_CR10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0022-2275(20)41527-5","volume":"33","author":"E Campos","year":"1992","unstructured":"Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoprotein isolated from human plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res. 1992;33:369\u201380.","journal-title":"J Lipid Res."},{"key":"189_CR11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0022-2275(20)30142-5","volume":"43","author":"E Campos","year":"2002","unstructured":"Campos E, Kotite I, Blanche P, Mitsugi Y, Frost PH, Masharani U, et al. Properties of triglyceride-rich and cholesterol-rich lipoproteins in the remnant-like particle fraction of human blood. J Lipid Res. 2002;43:365\u201374.","journal-title":"J Lipid Res."},{"key":"189_CR12","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1161\/01.CIR.0000125278.58527.F3","volume":"109","author":"TB Twickler","year":"2004","unstructured":"Twickler TB, Dalinga-Thie GM, Cohn JD, Chapman MJ. Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype. Circulation. 2004;109:1918\u201325.","journal-title":"Circulation."},{"key":"189_CR13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cca.2005.12.013","volume":"367","author":"K Nakajima","year":"2006","unstructured":"Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta. 2006;367:36\u201347.","journal-title":"Clin Chim Acta."},{"key":"189_CR14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198208053070601","volume":"307","author":"PJ Nestel","year":"1982","unstructured":"Nestel PJ, Fidge NH, Tan MH. Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med. 1982;307:329\u201333.","journal-title":"N Engl J Med."},{"key":"189_CR15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0021-9150(83)90165-X","volume":"46","author":"D Ron","year":"1983","unstructured":"Ron D, Oren I, Aviram M, Better OS, Brook JG. Accumulation of lipoprotein remnants in patients with chronic renal failure. Atherosclerosis. 1983;46:67\u201375.","journal-title":"Atherosclerosis."},{"key":"189_CR16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000190133","volume":"76","author":"H Oda","year":"1997","unstructured":"Oda H, Yoshioka N, Nishda Y, Nishida Y, Kushihata S, Ito T, et al. Remnant-like particle cholesterol indicate atherogenic risk in patients on chronic hemodialysis. Nephron. 1997;76:7\u201314.","journal-title":"Nephron."},{"key":"189_CR17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosis.2007.03.015","volume":"197","author":"T Hayashi","year":"2008","unstructured":"Hayashi T, Hirano T, Taira T, Tokuno A, Mori Y, Koba S, et al. Remarkable increase of apolipoprotein B-48 level in diabetic patients with end-stage renal disease. Atherosclerosis. 2008;197:154\u20138.","journal-title":"Atherosclerosis"},{"key":"189_CR18","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1742-1241.2011.02862.x","volume":"66","author":"K Homma","year":"2012","unstructured":"Homma K, Homma Y, Yamaguchi Y, Shiina Y, Wakino S, Hayashi K, et al. Triglyceride-rich lipoproteins in chronic kidney disease patients undergoing maintenance hemodialysis treatment. Int J Clin Pract. 2012;66:394\u20138.","journal-title":"Int J Clin Pract."},{"key":"189_CR19","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1172\/JCI115499","volume":"88","author":"JL Witstum","year":"1991","unstructured":"Witstum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785\u201392.","journal-title":"J Clin Invest."},{"key":"189_CR20","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/01.ATV.20.10.2243","volume":"20","author":"S Toshima","year":"2000","unstructured":"Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscl Thromb Vasc Biol. 2000;20:2243\u20137.","journal-title":"Arterioscl Thromb Vasc Biol."},{"key":"189_CR21","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/01.CIR.103.15.1955","volume":"103","author":"S Ehara","year":"2001","unstructured":"Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955\u201360.","journal-title":"Circulation."},{"key":"189_CR22","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1161\/01.ATV.0000080379.05071.22","volume":"23","author":"P Holvoert","year":"2003","unstructured":"Holvoert P, Harris TB, Tracy RP, Verhamme P, Newman AB, Rubin SM, et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly. Findings from the health, aging, and body composition. Arterioscler Thromb Vasc Biol. 2003;23:1444\u20138.","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"Suppl 1","key":"189_CR23","first-page":"94A","volume":"35","author":"WJ Knowles","year":"1986","unstructured":"Knowles WJ, Haigh WB, Michaud GC. A monoclonal antibody-based immunoassay for hemoglobin A1c. Diabetes. 1986;35(Suppl 1):94A.","journal-title":"Diabetes"},{"key":"189_CR24","first-page":"307","volume":"22","author":"PC Kao","year":"1992","unstructured":"Kao PC, Robert L, Taylor BS, et al. C-peptide immunochemiluminometric assay developed from two seemingly identical polyclonal antisera. Ann Clin Lab Sci. 1992;22:307\u201316.","journal-title":"Ann Clin Lab Sci"},{"key":"189_CR25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0009-8981(91)90106-M","volume":"199","author":"A Noma","year":"1991","unstructured":"Noma A, Hata Y, Goto Y, et al. Quantification of serum apolipoprotein A-I, B, C-II, C-III, and E by turbidimetric immunoassay: reference values, age-, sex-related differences. Clin Chim Acta. 1991;199:147\u201358.","journal-title":"Clin Chim Acta."},{"key":"189_CR26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0009-8981(93)90062-9","volume":"223","author":"K Nakajima","year":"1993","unstructured":"Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti-apo Ai and apo B immunoaffinity mixed gel. Clin Chim Acta. 1993;223:53\u201371.","journal-title":"Clin Chim Acta."},{"key":"189_CR27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0005-2760(94)90100-7","volume":"1215","author":"K Kotani","year":"1994","unstructured":"Kotani K, Maekawa M, Kanno T, Kondo A, Toda N, Manabe M. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta. 1994;1215:121\u20135.","journal-title":"Biochim Biophys Acta."},{"key":"189_CR28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0021-9150(99)00012-X","volume":"145","author":"H Watanabe","year":"1999","unstructured":"Watanabe H, Miyashita Y, Murano T, Hiroh Y, Itoh Y, Shirai K. Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias. Atherosclerosis. 1999;145:45\u201350.","journal-title":"Atherosclerosis."},{"key":"189_CR29","first-page":"2789","volume-title":"The metabolic and molecular bases of inherited disease","author":"J Brunzell","year":"2001","unstructured":"Brunzell J, Deeb SS. Familial lipoprotein lipase deficiency, Aoc C-II deficiency, and hepatic lipase deficiency. In: Scriver SPR, Beaudet AL, Sly WS, Valle DV, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 2789\u2013815.","edition":"8"},{"key":"189_CR30","first-page":"287","volume":"6","author":"H Kutoh","year":"2014","unstructured":"Kutoh H, Hirate M, Ikeno Y. Teneligliptin as an initial therapy for newly diagnosed, drug na\u00efve subjects with type 2 diabetes. J Clin Res. 2014;6:287\u201394.","journal-title":"J Clin Res."},{"key":"189_CR31","first-page":"532","volume":"65","author":"M Kusunoki","year":"2015","unstructured":"Kusunoki M, Sato D, Nakamura T, et al. DPP-4 inhibitor teneligliptin improves insulin resistance and serum lipid profile in Japanese patients with type 2 diabetes. Drug Res. 2015;65:532\u2013624.","journal-title":"Drug Res."},{"key":"189_CR32","doi-asserted-by":"crossref","first-page":"28J","DOI":"10.1016\/S0002-9149(99)00355-0","volume":"84","author":"BV Howard","year":"1999","unstructured":"Howard BV. Insulin resistance and lipid metabolism. Am J Cardiol. 1999;84:28J\u201332J.","journal-title":"Am J Cardiol"},{"key":"189_CR33","first-page":"1020","volume":"2","author":"K Homma","year":"2014","unstructured":"Homma K, Homma Y, Shiina Y, Kanda T, Tokuyama H, Wakino S, et al. Plasma levels of coronary risk biomarkers in chronic kidney disease patients undergoing maintenance hemodialysis treatment. J Endocrinol Diabetes Obes. 2014;2:1020\u20133.","journal-title":"J Endocrinol Diabetes Obes."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-017-0189-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-017-0189-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-017-0189-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T02:20:49Z","timestamp":1659061249000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-017-0189-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,2]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["189"],"URL":"https:\/\/doi.org\/10.1007\/s40268-017-0189-5","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,2]]}}}